Loading…
Based on limited metadata, this warning letter issued to American Botanical Pharmacy in October 2018 involves biologics products, though the specific nature of the violations cannot be determined as the subject line is unavailable. Without access to the full letter text, the exact regulatory concerns and issuing office cannot be specified. The warning indicates that the FDA identified compliance issues significant enough to warrant formal notification, but additional details would be needed to characterize the violations and their scope.